Delivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating Peptide

ACS Appl Mater Interfaces. 2016 Oct 12;8(40):26613-26621. doi: 10.1021/acsami.6b09991. Epub 2016 Sep 27.

Abstract

Clinical development of siRNA has been hindered by the lack of an effective delivery system. Here, we report the construction of a novel siRNA delivery system, sTOLP, which is based on cell penetrating peptide oleoyl-octaarginine (OA-R8) modified multifunctional lipid nanoparticles. sTOLP nanoparticles are composed of a protamine complexed siRNA core, OA-R8, cationic and PEGylated lipids, and transferrin as a targeting ligand. sTOLP formulation was optimized and characterized in vitro and showed excellent gene silencing activity. In vivo, siRNA encapsulated in sTOLP exhibited potent tumor inhibition (61.7%) and was preferentially taken up by hepatocytes and tumor cells in HepG2-bearing nude mice without inducing immunogenicity or hepatic or renal toxicity. Furthermore, sTOLP-loaded siRNA had stability in circulation greater than that of free siRNA. These data demonstrated potential utility of sTOLP-mediated siRNA delivery in cancer therapy.

Keywords: cancer; cell penetrating peptide; drug delivery; lipid nanoparticles; multifunctional; siRNA.

MeSH terms

  • Animals
  • Cell-Penetrating Peptides
  • Hep G2 Cells
  • Humans
  • Lipids
  • Mice
  • Mice, Nude
  • Nanoparticles*
  • RNA, Small Interfering

Substances

  • Cell-Penetrating Peptides
  • Lipids
  • RNA, Small Interfering